Carotid Stenting and Mechanical Thrombectomy in Patients with Acute Ischemic Stroke and Tandem Occlusions: Antithrombotic Treatment and Functional Outcome


ABSTRACT

BACKGROUND AND PURPOSE: There is no consensus on the optimal antithrombotic medication for patients with acute ischemic stroke with anterior circulation tandem occlusions treated with emergent carotid stent placement and mechanical thrombectomy. The identification of factors influencing hemorrhagic risks can assist in creating appropriate therapeutic algorithms for such patients. This study aimed to investigate the impact of medical therapy on functional and safety outcomes in patients treated with carotid stent placement and mechanical thrombectomy for tandem occlusions.

MATERIALS AND METHODS: A multicenter retrospective study on prospectively collected data was conducted. Only patients treated with carotid stent placement and mechanical thrombectomy for tandem occlusions of the anterior circulation were included. Univariate and multivariate analyses were performed on preprocedural, procedural, and postprocedural variables to assess factors influencing clinical outcome, symptomatic intracranial hemorrhage, stent patency, and successful intracranial vessel recanalization.

RESULTS: Ninety-five patients with acute ischemic stroke and tandem occlusions were included. Good clinical outcome (mRS $\leq 2$) at 3 months was reached by 33 (39.3%) patients and was associated with baseline ASPECTS $\geq 8$ (OR $= 1.53$; 95% CI, 1.16–2.00), $\leq 2$ mechanical thrombectomy attempts (OR $= 0.71$; 95% CI, 0.55–0.99), and the absence of symptomatic intracranial hemorrhage (OR $= 0.13$; 95% CI, 0.03–0.51). Symptomatic intracranial hemorrhage was associated with a higher amount of intraprocedural heparin, ASPECTS $\leq 7$, and $\geq 3$ mechanical thrombectomy attempts. No relationships among types of acute antiplatelet regimen, intravenous thrombolysis, and symptomatic intracranial hemorrhage were observed. Patients receiving dual-antiplatelet therapy after hemorrhagic transformation had been ruled out on 24-hour CT were more likely to achieve functional independence and had a lower risk of symptomatic intracranial hemorrhage.

CONCLUSIONS: During carotid stent placement and mechanical thrombectomy for tandem occlusion treatment, higher intraprocedural heparin dosage ([$\geq 3000$ IU]) increased symptomatic intracranial hemorrhage risk when the initial ASPECTS was $\leq 7$, and mechanical thrombectomy needs more than one passage for complete recanalization. Antiplatelets antiplatelets use were safe, and dual-antiaggregation therapy was related to better functional outcomes.

ABBREVIATIONS: AIS = acute ischemic stroke; ICH = intracranial hemorrhage; MT = mechanical thrombectomy; sICH = symptomatic intracranial hemorrhage; TO = tandem occlusion

Tandem occlusions (TOs) occur in up to 16%–20% of patients with acute ischemic stroke of the anterior cerebral circulation and are defined as a combined extracranial-intracranial cervical ICA lesion (complete occlusion or $\geq 90\%$ stenosis according to the NASCET criteria) and ipsilateral occlusion of proximal intracranial large vessels (ICA, the M1 and/or M2 segment of the middle cerebral artery).

Acute ischemic stroke (AIS) caused by TOs is generally associated with a poor prognosis when left untreated.

Please address correspondence to Valerio Da Ros, MD, Department of Biomedicine, Interventional Neuroradiology unit, University of Rome Tor Vergata, Viale Oxford B1, Rome, Italy; e-mail: darosvalerio@gmail.com

Indicates article with supplemental on-line tables.

http://dx.doi.org/10.3174/ajnr.A6768
Although intravenous thrombolysis with tPA remains part of the criterion standard treatment, tandem occlusions respond poorly to intravenous thrombolysis alone, likely due to the poor responsiveness of large thrombi to enzymatic digestion. Because intracranial vessel recanalization is the most powerful predictor of favorable clinical outcome, endovascular therapy is the standard of care for tandem occlusions.7 However, the most appropriate interventional strategy to manage the extracranial carotid disease remains controversial.2-7

Systematic reviews and post hoc analyses reported similar clinical outcomes at 3-month follow-up in patients with acute ischemic stroke and tandem occlusions treated with carotid stent placement or angioplasty. Conversely, a recent meta-analysis, a prospective nonrandomized trial, and the international multicenter Thrombectomy in TANdem Occlusion (TITAN) and Systematic Evaluation of Patients Treated with Stroke Devices for Acute Ischemic Stroke (STRATIS) Registry suggested better outcomes and higher recanalization rates for patients undergoing carotid stent placement.

The best antiplatelet/anticoagulant management to reduce the risk of postinterventional symptomatic intracranial hemorrhage (sICH) and prevent stent re-occlusion in these patients remains a matter of ongoing debate. Because emergent carotid stent placement during acute ischemic stroke requires antithrombotic agents, this strategy may be less appealing due to the intracranial hemorrhage (ICH) risk, especially for patients already receiving intravenous thrombolysis. Moreover, as addressed by the TITAN investigators, the use of intraprocedural heparin in tandem occlusions failed to demonstrate better functional, angiographic, or safety outcomes. So far, little evidence exists to guide the medical therapy of tandem occlusions treated with carotid stent placement, and high-quality analyses and randomized controlled trials are needed. This study aimed to investigate the impact of medical therapy on functional and safety outcomes in patients treated with carotid stent placement and mechanical thrombectomy for tandem occlusions.

MATERIALS AND METHODS

Study Design

We retrospectively evaluated all consecutive patients admitted with acute ischemic stroke between January 2018 and December 2019 in 5 Italian neurointerventional centers.

We included in this study only patients treated with emergent carotid stent placement and mechanical thrombectomy for a tandem occlusion, defined as an extracranial ICA lesion (complete occlusion or ≥90% stenosis according to the NASCET criteria) and an ipsilateral proximal intracranial large-vessel occlusion (intracranial ICA, the M1 and/or M2 segment of the middle cerebral artery) confirmed at initial cerebral angiography. Eligibility for intravenous thrombolysis and endovascular treatment was evaluated at each center according to the American Heart Association/American Stroke Association guidelines.

Preprocedural, procedural, 24- to 48-hour postprocedural, discharge, and 3-month data were prospectively collected. No ethics committee approval was required for this retrospective observational study.

We evaluated the following variables: demographic characteristics (ie, age, sex), cardiovascular risk factors (ie, atrial fibrillation, arterial hypertension, diabetes mellitus, hypercholesterolemia, smoking, previous cardio-cerebrovascular accidents), clinical and radiologic assessments (ie, mRS, NIHSS score, imaging characteristics [ie, ASPECTS]), stroke etiology according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification, stroke side, hemorrhagic transformation, stent patency, procedural time, (ie, onset-to-groin time, onset-to-recanalization time), number of mechanical thrombectomy (MT) attempts, type of stent (single- or dual-layer), and medical therapy (ie, preprocedural medications, intra- and postprocedural anticoagulant/antiplatelet protocols).

Good clinical outcome was defined as mRS 0–2 at 3-month follow-up, and favorable clinical outcome, as mRS 0–3.

Imaging Evaluation

All CT scans were obtained with 64 slices using a helicoid acquisition (GE LightSpeed VCT 64; GE Healthcare). At each institution, 2 neuroradiologists independently analyzed preprocedural and Systematic CT scans. Any disagreement was resolved by consensus with a third neuroradiologist (ie, head of the department). The cervical ICA occlusion was included in the TOAST classification on DSA, according to clinical and angiographic imaging characteristics. Successful recanalization was defined as modified TICI 2b–3 on DSA.

CT angiography was used to assess stent patency within 72 hours from treatment. Acute in-stent occlusion was defined as occlusion of the carotid stent within 72 hours after stent placement.

Symptomatic intracranial hemorrhage (sICH) was defined as parenchymal hematoma type 1 or 2 using the European Cooperative Acute Stroke Study (ECASS) III grading, according to imaging at 24 hours, associated with an increase of at least 4 NIHSS points within 24 hours, or resulting in death.

Emergent Carotid Stent Placement and MT

There were no technical restrictions to perform cervical ICA stent placement and intracerebral mechanical thrombectomy. Each center independently decided the stent type (ie, single-layer stent or dual-layer stent) and the mechanical thrombectomy technique (ie, aspiration and/or stent retriever) according to their experience.

Anticoagulation/Antiaggregation

For each patient, we assessed preprocedural, intraprocedural, and postprocedural medications, independently decided at each institution.

IV heparin sodium use was administered at the discretion of each center. The total amount of IV heparin was calculated on the basis of the speed of infusion, use of a bolus, and time from first infusion to the end of the procedure.

In patients already receiving antiplatelet medications, a single antiplatelet therapy was defined as a regular dosage of aspirin (Bayer) (ie, up to 300 mg) or clopidrogel 75 mg. In patients without antiplatelet medication, a dose of 500 mg of intravenous lysine acetylsalicylate administered before deployment of carotid stent placement was considered a regular single dosage. Dual-antiplatelet therapy was defined as a treatment with combined...
medications (eg, aspirin with clopidogrel) or a double regular dose of a single drug (eg, lysine acetylsalicylate, 1000 mg).

**Statistical Analysis**
Continuous variables were reported as mean ± SD or median with range, and categoric variables, as number and percentage. Contingency analyses for categoric variables were performed using the exact $\chi^2$ test.

Group comparisons were performed with the ANOVA and univariate logistic regression analyses to identify factors influencing clinical outcomes, stent patency, successful revascularization, and sICH. A 2-sided $P$ value < .05 indicated statistical significance. The multivariate analysis was performed using a general linear regression model (MANOVA), with a stepwise backward elimination procedure; a separate ANOVA was conducted for each dependent variable at an $\alpha$ level of .025. Analyses were performed using SPSS, Version 23.0 (IBM).

**RESULTS**

**Study Population**
Between January 2018 and December 2019, one thousand eighty patients admitted with acute ischemic stroke underwent mechanical thrombectomy; 214 patients (19.8%) presented with extracranial/intracranial tandem occlusions, of whom 95 patients (44.4%) received emergent carotid stent placement (flow chart in the Figure). The characteristics of the study population are presented in Table 1.

Fifty-six patients (58.9%) presented with a left-hemispheric stroke. Median baseline ASPECTS was 8, and the NIHSS score was 16.8. Forty-five patients (47.4%) were treated with mechanical thrombectomy plus intravenous thrombolysis. The mean onset-to-groin time was 284.5 ± 156.4 minutes, the mean onset-to-recanalization time was 376.7 ± 168.3 minutes, and the mean procedural time was 90.6 ± 58.2 minutes.

**Clinical and Angiographic Outcomes**
A successful intracranial recanalization (modified TICI 2b–3) was achieved in 58 of 95 patients (61.1%): TICI 3 in 31 (32.6%), TICI 2c in 5 (5.3%), and TICI 2b in 22 (23.2%). The rate of unsuccessful recanalization was 38.9%: TICI 2a in 28 patients (29.5%), TICI 1 in 3 (3.2%), and TICI 0 in 6.3%.

The rate of postprocedural sICH was 27.7%. Parenchymal hematoma type 1 occurred in 12 (12.7%) patients, and parenchymal hematoma type 2, in 14 (14.9%) patients. Clinical follow-up at 3 months from stroke was available in 84 patients: Thirty-three (39.3%) were functionally independent (mRS 0–2), and 47 (56%) achieved a favorable outcome (mRS 0–3).

**Management of Tandem Lesions**
Emergent carotid artery stent placement was performed in all patients. In 87 patients, a single-layer carotid stent was used, and 8 patients were treated with a dual-layer carotid stent.

**Factors Influencing Clinical Outcomes: ANOVA, Univariate, and Multivariate Analyses**
The subgroup comparison of patients with functional independence (mRS 0–2) and dependence at 3-month follow-up is presented in On-line Table 1. Patients with good clinical outcome were younger (mean age, 61.4 versus 65.9 years), presented with shorter onset-to-recanalization time (median, 317.5 versus...
360 minutes), had a higher rate of successful intracerebral re-
canalization (modified TICI ≥ 2b: 75.8% versus 52.9%), were 
more commonly prescribed postprocedural dual-antiplatelet 
therapy (67.9% versus 25.9%), and showed lower rates of 
sICH (9.1% versus 42%). All other cofactors were not statisti-
cally different between groups. The univariate logistic regres-
sion analysis is presented in On-line Table 2.

Factors associated with a good clinical outcome were 
higher baseline ASPECTS (OR = 1.53; 95% CI , 1.16–2; P = .002), lower 
rates of sICH (OR = 0.13; 95% CI, 0.37–0.51; P = .001), and ≤2 MT 
Attempts (OR = 0.71; 95% CI, 0.55–0.99; P = .04). Moreover, 
those patients receiving dual-antiplatelet therapy after hemor-
rhagic transformation had been ruled out on 24-hour CT had 
higher chances of functional independence at 3-month follow-
up (OR = 6.03; 95% CI, 1.87–19.44; P = .003).

All other intraprocedural or postprocedural anticoagulant/anti-
platelet protocols were not associated with good clinical outcome.

The multivariate general linear analysis (MANOVA) reported 
a relevant difference between patients with and without good 
clinical outcome when considered jointly on the variables of base-
line ASPECTS, sICH, postprocedural dual-antiplatelet therapy, 
and number of MT attempts.

There was a significant difference between patients with and 
without good clinical outcome on baseline ASPECTS, F (1–53) = 8.57,  
P = .001, partial η² = 0.14, with functionally independent patients 
having higher mean ASPECTS on baseline CT (8.4 ± 0.4; 95% CI, 
7.9–9.2) versus dependent patients (6.9 ± 0.4; 95% CI, 6–7.7).

The multivariate analysis confirmed the association with sICH 
(negative correlation; P = .005) and postprocedural dual-antiplate-
let therapy (positive correlation; P = .003). Moreover, mean me-
chanical thrombectomy attempts of 1.9 ± 0.3 (95% CI, 1.3–2.5; 
P = .004) were associated with good clinical outcome versus de-
pendent patients undergoing 3.2 ± 0.3 (95% CI, 2.6–3.9) attempts 
to recanalize the intracerebral occlusion.

**Factors Influencing Successful Recanalization and Stent 
Patency: ANOVA and Univariate Analysis**

The subgroup comparison of patients with successful and unsuc-
sessful intracerebral recanalization is presented in On-line Table 1.

The intracerebral large-vessel occlusion was more often success-
fully recanlized in patients presenting with left-hemispheric stroke 
(69% versus 43.2%), higher baseline ASPECTS (median, 8 versus 7), 
and faster onset-to-groin time (median, 236 versus 275 minutes).
Moreover, a trend toward successful recanalization (P = .052) was 
observed for patients receiving intraprocedural heparin. The univar-
te logistic regression analysis is presented in On-line Table 2.

The only factors associated with a successful recanalization 
were a left-hemispheric stroke (OR = 2.91; 95% CI, 1.23–6.86; 
P = .01) and ≤2 mechanical thrombectomy attempts (OR = 0.69; 
95% CI, 0.51–0.93; P = .01).

The comparison of the available data on stent patency within 
72 hours reported a higher rate of acute in-stent occlusion for 
dual-layer stent compared with single-layer stent (4/5 patients versus 10/ 
59 patients; 80% versus 16.9%; P < .001). A similar result was 
obtained by univariate logistic regression analysis (On-line Table 2) 
for dual-layer stent patency (OR = 0.05; 95% CI, 0.005–0.50; 
P = .007).

**Factors Influencing Symptomatic Intracerebral 
Hemorrhage: ANOVA, Univariate, and Multivariate 
Analyses**

The subgroup comparison of patients with and without sICH is 
presented in On-line Table 1. The only factor associated with sICH 
was a lower baseline ASPECTS (median, 6.5 versus 8) confirmed by 
univariate logistic regression analysis (On-line Table 2; P = .009).
Moreover, those patients receiving dual-antiplatelet therapy after 
hemorrhagic transformation had been ruled out on 24-hour CT 
had less chance of sICH (OR = 2.4; 95% CI, 1–5.8; P = .02).

The multivariate general linear analysis (MANOVA) reported 
a significant difference between patients with and without symp-
tomatic ICH when considered jointly on the variables baseline 
ASPECTS, intraprocedural heparin, and number of mechanical 
thrombectomy attempts, the Wilk Λ = 0.8, F (3.80) = 6.03, 
P = .001, partial η² = 0.18.

There was a significant difference between patients with and 
without sICH in intraprocedural heparin administration, F 
(1–84) = 6.4, P = .01, partial η² = 0.07, with patients with sICH 
in patients receiving higher amounts of heparin (mean = 3547 ± 
588 IU; 95% CI, 2377–4718 IU) compared with patients without sICH 
(1817 ± 339 IU; 95% CI, 1141–2493 IU).

There was a significant difference between patients with and 
without sICH in the number of mechanical thrombectomy attempts, 
F (1–84) = 32.14, P = .002, partial η² = 0.1, with sICH in patients treated with a higher number of passes 
(mean, 3.3 ± 0.3; 95% CI, 2.6–4.1) compared with those without 
sICH (1.9 ± 0.2; 95% CI, 1.5–2.4).

**DISCUSSION**

In this study, we assessed functional outcome and complications 
in patients with acute ischemic stroke and tandem occlusions 
treated with emergent carotid stent placement and mechanical 
thrombectomy. We focused our multicenter retrospective analy-
sis on this specific subgroup of patients with special regard for 
medical management to respond to the demanding questions 
raised after the recently reported higher successful recanalization 
rates and better clinical outcome in tandem occlusions managed 
with carotid stent placement.13–16

We found that a large ischemic core at the initial CT scan 
(ASPECTS ≤ 7), >2 mechanical thrombectomy attempts, 
and ≥3000 IU of intraprocedural heparin were significant predictors 
of sICH (Table 2). Functional independence was related to a 
small ischemic core (ASPECTS ≥ 8) and with the first-passages 
effect (ie, successful recanalization obtained with ≤2 mechanical 
thrombectomy attempts) (Table 2). Moreover, both single- and 
dual-antiplatelet therapy seem safe in emergent carotid stent 
placement, even if patients receive intravenous thrombolysis. 
Despite these results differing from those reported by van de 
Graaf et al,20 they are in accordance with the most recent data 
from the TITAN registry.29
Furthermore, patients receiving dual-antiplatelet therapy after ICH had been ruled out on postprocedural CT had higher chances of functional independence at 3 months from stroke, confirming the safety profile of antiplatelet therapy. This finding is in line with the study by Zhu et al., which reported a lower 90-day mortality rate in the antiplatelet therapy group.

Regarding anticoagulation, the intra procedural heparin dosage influenced the development of sICH. While we did not observe an increased risk of ICH (ie, hemorrhagic infarction or parenchymatous hematoma) within 24 hours from treatment in patients receiving low-dose intra procedural heparin (ie, <3000 IU), consistent with previous reports, low-dose heparin was not related to higher reperfusion rates. On the contrary, a higher dose of intra procedural heparin (ie, ≥3000 IU) was associated with sICH without improvement in the rate of successful recanalization or stent patency.

Heparin is commonly used to reduce the risk of re-occlusion and distal embolization during endovascular treatment, and post hoc analyses from the Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO 2) and Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trials showed its utility in obtaining good functional outcome without increasing the risk of hemorrhagic complications. However, the most recent results from large multicenter registries did not find differences between patients with and without heparin treatment in terms of good outcome or successful revascularization rates.

In our series, the overall sICH risk seems higher compared with the TITAN registry. The explanation of this discrepancy may reside in differences among the study populations. In our analysis, we included only patients who underwent emergent carotid stent placement. Thus, most of the included patients received a mixture of antiplatelet therapy, intravenous thrombolysis, and heterogeneous doses of intra procedural heparin; in contrast, in the TITAN registry, the analysis of the effect of anticoagulants was based only on patients who received a low dose of heparin.

This multicenter analysis has some limitations. First, the observational and nonrandomized design is subject to methodologic biases inherent in this form of study. Second, although only experienced neuroradiologists assessed data at each institution, we did not confirm our findings using a core lab assessment of brain imaging. Third, despite the effort to establish a comprehensive multicenter registry, there may be a concerning risk of bias due to patients lost to follow-up and missing data in the retrospective dataset. In our study, dual-layer stents represented an independent factor related to in-stent thrombosis, as previously reported by Yilmaz et al., however, the small group of 8 with dual-layer stents did not allow running a powerful subgroup analysis comparing single- and dual-antiplatelet therapy in dual-layer stents.

Finally, the medical treatment strategy was left to the interventionist’s discretion with heterogeneous drug dosages and administration times.

**CONCLUSIONS**

In the literature, there are few data to guide management of tandem occlusions in patients with acute ischemic stroke, and optimal antithrombotic therapy remains to be assessed for patients treated with emergent carotid artery stent placement. In our analysis, regular doses of intra procedural heparin (≥3000 IU) were associated with sICH, antiplatelets were safe, and dual-antithrombolytic therapy was related to better functional outcomes. The current findings may inform clinical practice and provide support for a prospective randomized controlled trial aimed at assessing endovascular treatment of patients with tandem occlusions.

**REFERENCES**


